VS-7375 enters the clinic in KRAS G12D-mutated solid tumors
Verastem has moved VS-7375 into a phase 1/2 program aimed at one of the most closely watched oncogenic targets in solid tumors: KRAS G12D. The study is open-label and is designed to evaluate the agent both as monotherapy and in combination across advanced, unresectable, or metastatic disease. Its scope is broad, but the biology is sharply focused. KRAS G12D sits at the center of a large fraction of pancreatic, lung, and colorectal cancers, and a drug that can inhibit the mutant protein in both its active and inactive states could alter a pathway that has resisted treatment for decades.
This is not a signal of proven benefit. It is a carefully staged attempt to determine whether direct KRAS G12D inhibition can be delivered safely enough, and in enough patients, to justify deeper efficacy testing.
A trial built around molecular selection rather than tumor origin
The study enrolls adults with histologic or cytologic evidence of locally advanced unresectable or metastatic solid tumors carrying a KRAS G12D mutation. Eligible participants must have measurable disease by RECIST v1.1, an ECOG performance status of 0 or 1, adequate organ and cardiac function, and recovery to grade 1 or baseline from prior treatment-related adverse events. The protocol also requires highly effective contraception, reflecting standard safeguards for an interventional oncology study with an investigational targeted agent.
The inclusion strategy is notable because it centers on the mutation itself rather than restricting enrollment to a single histology. Pancreatic ductal adenocarcinoma, non-small cell lung cancer, colorectal cancer, and other solid tumors appear in the study’s disease list. That design reflects the biology of KRAS-driven cancer: once the same oncogenic switch is present, the therapeutic logic can cross organ boundaries even when the clinical phenotype differs.
Early-phase design will test safety before any efficacy claim can harden
The trial began on 2025-06-24 and is estimated to run through December 2028, with both primary completion and study completion projected for that month. Enrollment is estimated at 616 participants, a sizable footprint for a first-in-human and expansion-stage development program. The combination of phase 1 and phase 2 signals a staged approach: the first task is to define tolerability, dose behavior, and early pharmacologic activity; the later task is to see whether the signal, if present, can be reproduced in disease-specific cohorts.
The study includes multiple treatment paths. Alongside VS-7375, the protocol lists cetuximab, carboplatin plus pemetrexed plus pembrolizumab, gemcitabine plus nab-paclitaxel, pembrolizumab, defactinib, midazolam, and repaglinide. The appearance of these agents suggests a development plan that extends beyond single-agent inhibition into combination strategies and drug-interaction or pharmacology assessment. In KRAS-driven disease, that matters because downstream signaling, adaptive resistance, and parallel pathway activation often blunt the impact of a lone inhibitor.
A KRAS blocker that fails in the clinic usually does so because the tumor reroutes around it.
Why KRAS G12D remains such an important target
KRAS mutations drive constitutive proliferative signaling, survival advantages, and resistance to conventional therapy. The G12D substitution is especially relevant in pancreatic cancer, where KRAS alterations are nearly defining, and in subsets of lung and colorectal cancer. If a molecule can inhibit KRAS G12D directly, it may suppress the signaling node that feeds MAPK and related growth pathways at their source rather than trying to block the cascade after it has already been activated.
The protocol identifies VS-7375 as a KRAS G12D “ON/OFF” inhibitor, language that implies coverage of both nucleotide states of the protein. From a pharmacologic standpoint, that kind of mechanism is attractive because KRAS cycles between active and inactive conformations, and tumors can exploit that dynamic to evade narrower inhibitors. Combination partners listed in the protocol also make mechanistic sense: cetuximab can blunt upstream receptor signaling in colorectal cancer, pembrolizumab can engage immune-mediated tumor control in selected settings, and cytotoxic doublets remain the backbone for pancreatic and lung cancer care.
Eligibility criteria indicate a fitter population than routine practice
The study’s eligibility requirements will shape the patient population substantially. Adults must have adequate performance status, preserved organ and cardiac function, and sufficient recovery from prior therapy. Recent major surgery, recent chemotherapy, recent radiotherapy outside palliative use, recent immunotherapy, and recent investigational drug exposure are all exclusionary within specified windows before Cycle 1 Day 1. Those criteria reduce confounding from lingering toxicity and make early safety attribution more reliable, but they also mean the trial population will be healthier than many patients seen in a late-line oncology clinic.
That difference affects interpretation. A tolerable toxicity profile in this setting would still need confirmation in a broader real-world population, especially in patients with pancreatic cancer who often carry biliary obstruction, weight loss, hepatic dysfunction, or rapidly declining performance status.
Geography and access shape who can enroll
Fifteen recruiting sites span the United States and Australia, including major cancer centers in Los Angeles, Baltimore, Boston, Ann Arbor, St. Louis, New York, Philadelphia, Nashville, Houston, Salt Lake City, Charlottesville, Fairfax, Seattle, Sydney, and Frankston. The networked footprint suggests an intention to recruit patients across several high-volume academic and community oncology environments. Centralized molecular screening is likely to be essential, since KRAS G12D testing will determine who can enter the study.
For clinicians, the practical question is whether a patient with refractory KRAS G12D-mutated disease can be identified early enough and referred while organ function still allows trial participation. For patients, the more immediate issue is simple: this is one of the few current studies built specifically around a mutation that has long been considered hard to drug.
The next readout will be defined by safety, dose, and molecular response signals
No results have been posted yet, so the clinical weight of this trial rests on its structure rather than its outcome. The first useful readouts will likely be dose tolerance, adverse-event patterns, and early evidence of target engagement or response across tumor types. If the drug can be paired safely with one or more of the listed regimens, the study could also clarify where combination therapy is necessary and where monotherapy is enough.
What remains unresolved is whether a KRAS G12D inhibitor can produce durable control without triggering prohibitive toxicity or rapid adaptive escape. The answer will depend on the eventual data from the phase 1/2 program, not on the promise of the target alone.